SCHEMBL21392897

SCHEMBL21392897

C=CC(=O)Nc1ccc(Oc2cccc(-c3ccoc3)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 2/20 0.60
LPAR1 Q92633 1/20 0.49
LPAR2 Q9HBW0 1/20 0.49
LPAR3 Q9UBY5 1/20 0.49
CNR1 P21554 1/20 0.48
BTK Q06187 8/20 0.47
EGFR P00533 6/20 0.47
MTNR1A P48039 2/20 0.46
MTNR1B P49286 2/20 0.46
LTA4H P09960 1/20 0.44
ALDH1A1 P00352 1/20 0.43
ERBB2 P04626 2/20 0.43
MAP2K7 O14733 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21392905 0.81 TGM2 (0.63) TGM2LPAR1LPAR2LPAR3BTK
SCHEMBL9017578 0.77 TGM2 (1.00) TGM2LPAR1LPAR2LPAR3EGFR
SCHEMBL21392902 0.76 TGM2 (0.71) TGM2LPAR1LPAR2LPAR3BTK
SCHEMBL8151744 0.76 MTNR1B (0.74) TGM2LPAR1LPAR2LPAR3MTNR1A
SCHEMBL14341775 0.76 TGM2 (0.86) TGM2LPAR1LPAR2LPAR3EGFR
SCHEMBL24168800 0.73 TGM2 (0.66) TGM2LPAR1LPAR2LPAR3BTK
SCHEMBL22732031 0.73 TGM2 (0.74) TGM2LPAR1LPAR2LPAR3BTK
SCHEMBL21392903 0.71 TGM2 (0.59) TGM2BTKEGFRALDH1A1MAPT
SCHEMBL22732028 0.71 TGM2 (0.62) TGM2LPAR1LPAR2LPAR3BTK
SCHEMBL20456243 0.70 TGM2 (0.73) TGM2ALDH1A1MAP2K7MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 TGM2 2225/4885LPAR1 2398/4885LPAR2 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.